Major Breakthroughs in Atopic Dermatitis Treatment
Almirall S.A. has unveiled promising results from a long-term study on EBGLYSS® (lebrikizumab). The findings reveal that over 80 percent of adults and adolescents suffering from moderate-to-severe atopic dermatitis experienced sustained skin clearance after treatment lasting up to three years. These results stem from thorough clinical trials, including the ADvocate 1 and 2 studies, along with further analyses conducted in the ADjoin long-term extension study.
Lebrikizumab’s Effect on Patient Well-Being
Lebrikizumab functions as an interleukin-13 (IL-13) inhibitor, crucially disrupting the inflammatory processes linked to atopic dermatitis. This condition can dramatically impair the quality of life for those affected, leading to distressing symptoms like severe itching, thickened skin, and increased risk of infections. The findings presented by Almirall highlight the potential of this advanced biologic treatment to offer lasting relief from these debilitating effects.
Long-Term Results and Effectiveness Rates
The analysis revealed that 84 percent of patients receiving monthly doses of lebrikizumab and 83 percent of those on bi-weekly treatments maintained either clear or nearly clear skin after three years. Furthermore, notable improvements were observed, with 87 percent of the monthly treatment group achieving or sustaining at least a 90 percent reduction in disease activity by the three-year mark. Meanwhile, 79 percent of participants receiving bi-weekly doses reported similar success, marking a significant accomplishment for chronic treatment efficacy.
Lebrikizumab’s Safety and Tolerability
During the ADjoin study, lebrikizumab showcased a safety profile consistent with earlier research, revealing no new safety concerns after three years of treatment. Most side effects reported by patients were mild to moderate, which enhances the appeal of this treatment option. Importantly, serious adverse events that led to discontinuation were rare, affecting less than three percent of study participants.
Ongoing Research and Development
Almirall is actively pursuing further studies to unlock the full potential of lebrikizumab, ensuring ongoing evaluations will deepen the understanding of its long-term efficacy and safety. Future results are anticipated to be disclosed at various medical conferences, further solidifying its role within the field of dermatology.
Global Availability and Reach
The lebrikizumab treatment has received regulatory approval in the European Union, the UK, Japan, Switzerland, and the United States, reflecting its wide-ranging application for managing atopic dermatitis across various regions. It is currently prescribed in several countries, including Germany, the UK, Norway, Denmark, Spain, and the Czech Republic, greatly improving access for patients who need it.
About Almirall and Its Commitment to Innovation
Founded in 1944 and based in Barcelona, Almirall is a global pharmaceutical company dedicated to delivering innovative solutions in medical dermatology. The company collaborates closely with scientists and healthcare professionals to improve patients' lives. Almirall’s commitment to providing transformative treatments is evident through its extensive clinical programs aimed at meeting dermatological needs.
Frequently Asked Questions
What is lebrikizumab used for?
Lebrikizumab is primarily indicated for the treatment of moderate-to-severe atopic dermatitis in both adults and adolescents.
How long did the clinical trials for lebrikizumab last?
The trials assessed the efficacy of lebrikizumab over a period of three years, emphasizing long-term results for patients.
What were the main findings regarding lebrikizumab’s effectiveness?
Over 80% of patients maintained clear skin, with significant improvements in their disease severity reported.
What safety concerns were associated with lebrikizumab?
The treatment showed a safety profile akin to previous studies, primarily involving mild or moderate side effects.
In which countries is lebrikizumab available for prescription?
Lebrikizumab is prescribed in several countries, including Germany, the UK, and various others throughout Europe and Japan.
